Chad A Bousman1, Philip Jaksa, Christos Pantelis. 1. aDepartment of Psychiatry, Melbourne Neuropsychiatry Centre bDepartment of General Practice cFlorey Institute of Neuroscience and Mental Health, The University of Melbourne dNorth Western Mental Health, Melbourne Health, Parkville eDepartment of Electrical and Electronic Engineering, Centre for Neural Engineering, University of Melbourne, Carlton South, Victoria fACT Health, Canberra, Australian Capital Territory, Australia.
Abstract
OBJECTIVE: The aim of this study was to systematically assess commercial pharmacogenetic tests relevant to prescribing in psychiatry, with specific attention on CYP2D6 and CYP2C19 star allele coverage as well as compliance with consensus recommendations for pharmacogenetic test result reporting. MATERIALS AND METHODS: The CYP2D6 and CY2C19 star (*) allele contents of 20 pharmacogenetic test panels were compared and their test results reports were evaluated on the basis of consensus reporting recommendations published by The Centers for Disease Control and Prevention as well as the Clinical Pharmacogenetics Implementation Consortium. RESULTS: Most test panels included the major CYP2D6 (*2, *4, *5, *10, *17) and CYP2C19 (*2, *3, *17) alleles, but no two test panels contained the same combination of CYP2D6 and CYP2C19 alleles. Of the 20 pharmacogenetic reports that we evaluated, none fulfilled all the recommendations and no recommendation was fulfilled by all tests. CONCLUSION: Consensus has yet to be reached on which CYP2D6 and CYP2C19 star alleles to include on pharmacogenetic testing panels and pharmacogenetic results reporting could be considerably improved. Collaboration between test manufacturers and end-users is required to narrow the gap between the availability and integration of these pharmacogenetic-based decision-support tools into routine practice.
OBJECTIVE: The aim of this study was to systematically assess commercial pharmacogenetic tests relevant to prescribing in psychiatry, with specific attention on CYP2D6 and CYP2C19 star allele coverage as well as compliance with consensus recommendations for pharmacogenetic test result reporting. MATERIALS AND METHODS: The CYP2D6 and CY2C19 star (*) allele contents of 20 pharmacogenetic test panels were compared and their test results reports were evaluated on the basis of consensus reporting recommendations published by The Centers for Disease Control and Prevention as well as the Clinical Pharmacogenetics Implementation Consortium. RESULTS: Most test panels included the major CYP2D6 (*2, *4, *5, *10, *17) and CYP2C19 (*2, *3, *17) alleles, but no two test panels contained the same combination of CYP2D6 and CYP2C19 alleles. Of the 20 pharmacogenetic reports that we evaluated, none fulfilled all the recommendations and no recommendation was fulfilled by all tests. CONCLUSION: Consensus has yet to be reached on which CYP2D6 and CYP2C19 star alleles to include on pharmacogenetic testing panels and pharmacogenetic results reporting could be considerably improved. Collaboration between test manufacturers and end-users is required to narrow the gap between the availability and integration of these pharmacogenetic-based decision-support tools into routine practice.
Authors: Kelly E Caudle; Nicholas J Keeling; Teri E Klein; Michelle Whirl-Carrillo; Victoria M Pratt; James M Hoffman Journal: Pharmacogenomics Date: 2018-06-19 Impact factor: 2.533
Authors: Cathy R Fulton; Marelize Swart; Thomas De Luca; Stephanie N Liu; Kimberly S Collins; Zeruesenay Desta; Brandon T Gufford; Michael T Eadon Journal: J Nurse Pract Date: 2018-11-02 Impact factor: 0.767
Authors: Abdullah Al Maruf; Mikayla Fan; Paul D Arnold; Daniel J Müller; Katherine J Aitchison; Chad A Bousman Journal: Can J Psychiatry Date: 2020-02-17 Impact factor: 4.356
Authors: Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk Journal: Clin Pharmacol Ther Date: 2019-12-09 Impact factor: 6.875
Authors: Mariana R Botton; Michelle Whirl-Carrillo; Andria L Del Tredici; Katrin Sangkuhl; Larisa H Cavallari; José A G Agúndez; Jorge Duconge; Ming Ta Michael Lee; Erica L Woodahl; Karla Claudio-Campos; Ann K Daly; Teri E Klein; Victoria M Pratt; Stuart A Scott; Andrea Gaedigk Journal: Clin Pharmacol Ther Date: 2020-07-22 Impact factor: 6.875